Rijista ta ƙare don Sabuwar gwaji a cikin tari mai tsayi

Trevi Therapeutics, Inc. wani kamfani ne na likitancin likitanci wanda ke haɓaka aikin binciken Haduvio ™ (nalbuphine ER). A yau, Trevi ya sanar da cewa ya kammala yin rajista da wuri don gwajin gwaji na Phase 2 da NALbuphine (CANAL) don maganin tari na yau da kullun a cikin marasa lafiya na fibrosis na huhu (IPF) biyo bayan sanarwar da aka yi a baya na ingantaccen sakamako daga ƙididdigar wucin gadi (N=26). ). Ƙarshen ingantaccen sakamako na farko ya nuna raguwar 77.3% a mitar tari na rana daga asali tare da amfani da Haduvio idan aka kwatanta da raguwar 25.7% tare da placebo, yana nuna raguwar 52% na placebo-daidaitacce a cikin ma'anar ma'anar geometric canji a cikin mitar tari na rana (p) <0.0001).

Saboda gwajin ya sami mahimmancin ƙididdiga a cikin bincike na wucin gadi, an sanar da rukunin yanar gizon cewa za su iya yin rajistar batutuwan da suka cancanta a riga an tantance su amma ba a buƙatar ƙarin daukar ma'aikata. Kimanin batutuwa 40 gabaɗaya an sanya su cikin binciken. Kamfanin ya ci gaba da tsammanin bayar da rahoton inganci da aminci kan cikakken jigon batutuwa a cikin kwata na uku na 2022.

IPF cuta ce mai tsanani, ƙarshen rayuwa inda tari ke ɗaya daga cikin mahimman alamun. An kiyasta cewa akwai majinyata IPF 130,000 a Amurka da fiye da marasa lafiya miliyan 1 da suka kasance a Amurka, inda kusan kashi 85% na waɗannan marasa lafiya ke fama da tari na yau da kullun. Babu wasu hanyoyin da aka yarda da su don maganin tari na yau da kullum a cikin IPF, kuma tari yakan saba da maganin antitussive. Marasa lafiya masu fama da tari na yau da kullun a cikin IPF na iya yin tari har sau 520 a kowace rana, wanda ke haifar da ƙara jin damuwa yayin da yake haifar da rashin numfashi. Matsalolin tari ko abubuwan da suka faru suna haifar da gaji mai mahimmanci, yunwar iska, ƙarancin iskar oxygen da wasu marasa lafiya kuma suna fuskantar rashin haƙori mai alaƙa da tari. Tasirin zamantakewa na tari na yau da kullun a cikin IPF yana ƙara haɓaka iyakantaccen ƙarfin motsa jiki, rage nisan tafiya da buƙatar amfani da ƙarin oxygen. Tari na yau da kullun a cikin IPF na iya zama farkon alamar asibiti na ayyukan cuta, gano marasa lafiya da ke cikin haɗarin ci gaba, hasashen lokaci zuwa mutuwa ko dashen huhu, kuma yana iya ba da gudummawa ga haɓakar ingantattun hanyoyin profibrotic da cutar da cutar a cikin IPF.